Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
Mehreen S. Datoo(University of Oxford), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Louis Fries(Novavax (United States)), Eli Rouamba(Institut de Recherche en Sciences de la Santé), Jenny M. Reimer(Novavax (Sweden)), Fernando Ramos Lopez(University of Oxford), Karim Derra(Institut de Recherche en Sciences de la Santé), Duncan Bellamy(University of Oxford), Rachidatou Soma(Institut de Recherche en Sciences de la Santé), Gregory M. Glenn(Agricultural Research Service), Katie Ewer(University of Oxford), Adrian V. S. Hill(University of Oxford), Alison M. Lawrie(University of Oxford), Faizatou Sorgho(Institut de Recherche en Sciences de la Santé), Hamtandi Magloire Natama(Research Institute of Health Sciences), Samuel Provstgaard-Morys(Serum Institute of India (India)), Umesh Shaligram(Serum Institute of India (India)), N. Félix André Ido(Serum Institute of India (India)), Aida Millogo(Serum Institute of India (India)), Marc Christian Tahita(Serum Institute of India (India)), Seydou Sawadogo(Institut de Recherche en Sciences de la Santé), Prisca Yameogo(Institut de Recherche en Sciences de la Santé), Florence Ouédraogo(Institut de Recherche en Sciences de la Santé), Hermann Sorgho(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Ousmane Traoré(Institut de Recherche en Sciences de la Santé), Daniel Valia(Institut de Recherche en Sciences de la Santé), Rachel Roberts(University of Oxford), Jeremy Aboagye, Innocent Valéa(Institut de Recherche en Sciences de la Santé), Matthew Cairns(University of London), Nicola Williams(University of Oxford)
Cited by 285
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451